- $34.93m
- $9.99m
- $4.01m
CervoMed posts smaller-than-expected Q1 net loss
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
CervoMed rises as experimental drug shows benefit in early-stage dementia patients
Pathology
Brief: CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates
Brief: Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies
Brief: Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform
CervoMed Q3 net loss widens
Brief: CervoMed Announces Alignment With FDA On Registration Path For Neflamapimod In Dementia With Lewy Bodies
Brief: CervoMed Strengthens Board With Appointment Of Life Sciences Business Strategy Leader David Quigley
U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy
U.S. STOCKS ON THE MOVE-United Rentals, Dell, Datadog
U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66
CervoMed rises after dementia drug shows promise in mid-stage study
Brief: Cervomed Appoints Matthew Winton, Ph.D., As Chief Commercial And Business Officer
CervoMed Inc expected to post a loss of 63 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-CervoMed, Talen Energy, PACCAR